FDA warned Amp Health that its website misbranded compounded semaglutide and tirzepatide with false maker and approval-implying claims.
What happened
In December 2025, FDA reviewed the website https://myamphealth.com and found it offered compounded semaglutide and tirzepatide drug products. FDA said the pictured labels name Amp Health in a way that falsely suggests it made the drugs, and website claims comparing the products to Wegovy, Ozempic, Saxenda, Mounjaro, and Zepbound imply FDA approval or evaluation that the compounded products do not have; FDA called the products misbranded, meaning their labeling or advertising is false or misleading.
What FDA found
The website’s pictured labels name Amp Health in a way that falsely suggests Amp Health made the compounded semaglutide and tirzepatide products.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website claims the products contain the same active ingredient as Wegovy, Ozempic, and Saxenda, implying FDA approval or evaluation.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website claims the products contain the same active ingredient as Mounjaro and Zepbound, implying FDA approval or evaluation.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receipt of misbranded drugs in interstate commerce, and delivery or proffered delivery of them, is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days of receipt, FDA asks Amp Health to send OCQC/CDER’s Office of Compliance a written response describing steps taken to fix the violations and prevent recurrence, with supporting documents. FDA also asks Amp Health to identify who makes the products, provide sample labeling, and address or modify the website claims.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounding pharmacies and makers whose products are sold through online platforms
- marketing and regulatory teams for online drug sellers
This is a summary. Read the original letter on fda.gov.